0001493152-23-043170.txt : 20231130 0001493152-23-043170.hdr.sgml : 20231130 20231130114517 ACCESSION NUMBER: 0001493152-23-043170 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20231130 ITEM INFORMATION: Material Modifications to Rights of Security Holders ITEM INFORMATION: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year ITEM INFORMATION: Regulation FD Disclosure ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20231130 DATE AS OF CHANGE: 20231130 FILER: COMPANY DATA: COMPANY CONFORMED NAME: ZyVersa Therapeutics, Inc. CENTRAL INDEX KEY: 0001859007 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 862685744 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-41184 FILM NUMBER: 231454646 BUSINESS ADDRESS: STREET 1: 217 W. MAIN STREET CITY: SOMERVILLE STATE: NJ ZIP: 08876 BUSINESS PHONE: 908-370-5102 MAIL ADDRESS: STREET 1: 217 W. MAIN STREET CITY: SOMERVILLE STATE: NJ ZIP: 08876 FORMER COMPANY: FORMER CONFORMED NAME: Larkspur Health Acquisition Corp. DATE OF NAME CHANGE: 20210426 8-K 1 form8-k.htm
false --12-31 0001859007 0001859007 2023-11-30 2023-11-30 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

 

FORM 8-K

 

CURRENT REPORT

 

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): November 30, 2023

 

ZYVERSA THERAPEUTICS, INC.

(Exact name of registrant as specified in its charter)

 

Delaware   001-41184   86-2685744
(State or other jurisdiction   (Commission   (I.R.S. Employer
of incorporation)   File Number)   Identification No.)

 

2200 N. Commerce Parkway, Suite 208  Weston, Florida   33326
(Address of principal executive offices)   (Zip Code)

 

(754) 231-1688

(Registrant’s telephone number, including area code)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
   
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
   
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
   
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of Each Class   Trading Symbol(s)   Name of each exchange on which registered
Common Stock, par value $0.0001 per share   ZVSA   The Nasdaq Global Market

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company ☒

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

 
 

 

Item 3.03 Material Modification to Rights of Security Holders.

 

To the extent required by Item 3.03 of Form 8-K, the information contained in Item 5.03 of this Current Report is incorporated herein by reference.

 

Item 5.03. Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year.

 

On November 30, 2023, ZyVersa Therapeutics, Inc. (the “Company”) filed a certificate of amendment to the Company’s Second Amended and Restated Certificate of Incorporation (the “Amendment”) with the Secretary of State of the State of Delaware relating to a 1-for-35 reverse stock split (the “Reverse Stock Split”) of the outstanding shares of the Company’s common stock (“Common Stock”). The Reverse Stock Split is expected to become effective om December 4, 2023 at 4:01 p.m., and the Common Stock is expected to begin trading on The Nasdaq Global Market on a Reverse Stock Split-adjusted basis on December 5, 2023 at market open. The Company’s stockholders previously approved the Reverse Stock Split and granted the board of directors the authority to determine the exact split ratio and when to proceed with the Reverse Stock Split at the Company’s Annual Meeting of Stockholders held on October 31, 2023 (the “Annual Meeting”). The Company’s board of directors subsequently approved the Reverse Stock Split in the ratio of 1-for-35.

 

The Amendment also increased, effective as of the filing of the Amendment with the Secretary of State of the State of Delaware, the authorized number of shares of the Company’s capital stock from 111,000,000 to 251,000,000 and the number of authorized shares of Common Stock from 110,000,000 to 250,000,000 (“Authorized Share Increase”).

 

The par value and other terms of the Common Stock were not affected by the Reverse Stock Split or Authorized Share Increase. The Company’s post-Reverse Stock Split Common Stock CUSIP number will be 98987D201.

 

A copy of the Amendment is attached to this Current Report on Form 8-K as Exhibit 3.1 and is incorporated by reference herein.

 

Item 7.01. Regulation FD Disclosure.

 

The Company issued a press release (the “Press Release”) on November 30, 2023 regarding the Reverse Stock Split and the Authorized Share Increase, a copy of which is furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information included under this Item 7.01 (including Exhibit 99.1) is furnished pursuant to Item 7.01 and shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall such information be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

 

Item 9.01. Financial Statements and Exhibits.

 

(d) Exhibits.

 

Exhibit No.   Description
      
3.1   Certificate of Amendment filed with the Delaware Secretary of State on November 30, 2023.
99.1   Press release of the registrant issued on November 30, 2023 (furnished pursuant to Item 7.01).
104   Cover Page Interactive Data File (embedded within the Inline XBRL document)

 

 
 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  ZYVERSA THERAPEUTICS, INC.
     
November 30, 2023 By: /s/ Stephen Glover
  Name: Stephen Glover
  Title: Chief Executive Officer

 

 

 EX-3.1 2 ex3-1.htm

 

Exhibit 3.1

 

CERTIFICATE OF AMENDMENT

OF

SECOND AMENDED AND RESTATED CERTIFICATE OF INCORPORATION

OF

ZYVERSA THERAPEUTICS, INC.

 

(Pursuant to Section 242 of the General Corporation Law of the State of Delaware)

 

ZyVersa Therapeutics, Inc., a corporation organized and existing under and by virtue of the General Corporation Law of the State of Delaware (the “Corporation”), does hereby certify as follows:

 

1.That a resolution was duly adopted by the Board of Directors of the Corporation pursuant to Section 242 of the General Corporation Law of the State of Delaware setting forth an amendment to the Second Amended and Restated Certificate of Incorporation of the Corporation and declaring said amendment to be advisable and that such amendment be submitted to the stockholders of the Corporation for their consideration, as follows:

 

RESOLVED: That the first paragraph of Article IV of the Second Amended and Restated Certificate of Incorporation of the Corporation be and hereby is deleted in its entirety and the following is inserted in lieu thereof:

 

“The Corporation is authorized to issue two classes of stock to be designated, respectively, “Common Stock” and “Preferred Stock.” The total number of shares of capital stock that the Corporation shall have authority to issue is 251,000,000. The total number of shares of Common Stock that the Corporation is authorized to issue is 250,000,000, having a par value of $0.0001 per share, and the total number of shares of Preferred Stock that the Corporation is authorized to issue is 1,000,000, having a par value of $0.0001 per share.

 

Effective as of December 4, 2023 at 4:01 p.m. Eastern Time (the “Reverse Stock Split Effective Time”), a one-for-thirty-five (1:35) reverse stock split of the Corporation’s Common Stock shall become effective, pursuant to which each thirty-five (35) shares of Common Stock issued and outstanding and held of record by each stockholder of the Corporation or issued and held by the Corporation in treasury immediately prior to the Reverse Stock Split Effective Time shall be reclassified and combined into one (1) validly issued, fully paid and nonassessable share of Common Stock automatically and without any action by the holder thereof upon the Reverse Stock Split Effective Time and shall represent one (1) share of Common Stock from and after the Reverse Stock Split Effective Time (such reclassification and combination of shares, the “Reverse Stock Split”). If, upon aggregating all of the shares of Common Stock held by a holder of Common Stock immediately following the Reverse Stock Split such holder would otherwise be entitled to a fractional share of Common Stock, the Corporation shall issue to such holder an additional fraction of a share of Common Stock as is necessary to round the number of shares of Common Stock held by such holder up to the nearest whole share, such that no person will hold fractional shares following the Reverse Stock Split.

 

 

 

Each stock certificate that, immediately prior to the Reverse Stock Split Effective Time, represented shares of Common Stock that were issued and outstanding immediately prior to the Reverse Stock Split Effective Time shall, from and after the Reverse Stock Split Effective Time, automatically and without the necessity of presenting the same for exchange, represent that number of whole shares of Common Stock after the Reverse Stock Split Effective Time into which the shares formerly represented by such certificate have been reclassified (including those fractional shares issued by the Corporation in connection with the Reverse Stock Split to round the number of shares held by such holder at the Reverse Stock Split Effective Time up to the nearest whole share); provided, however, that each person of record holding a certificate that represented shares of Common Stock that were issued and outstanding immediately prior to the Reverse Stock Split Effective Time shall receive, upon surrender of such certificate, a new certificate evidencing and representing the number of whole shares of Common Stock after the Reverse Stock Split Effective Time into which the shares of Common Stock formerly represented by such certificate shall have been reclassified (including those fractional shares issued by the Corporation in connection with the Reverse Stock Split to round the number of shares held by such holder at the Reverse Stock Split Effective Time up to the nearest whole share).”

 

2.That, at an annual meeting of stockholders of the Corporation, the aforesaid amendment was duly adopted by the stockholders of the Corporation.

 

3.That the aforesaid amendment was duly adopted in accordance with the applicable provisions of Section 242 of the General Corporation Law of the State of Delaware.

 

2
 

 

IN WITNESS WHEREOF, this Certificate of Amendment has been executed by a duly authorized officer of the Corporation on this 30th day of November, 2023.

 

  ZYVERSA THERAPEUTICS, INC.
     
  By: /s/ Stephen Glover
     
  Name: Stephen Glover
     
  Title: Chief Executive Officer

 

3

 EX-99.1 3 ex99-1.htm

 

Exhibit 99.1

 

ZyVersa Therapeutics, Inc. Announces Reverse Stock Split and Increase in Authorized Shares of Common Stock

 

WESTON, FL (November 30, 2023) - ZyVersa Therapeutics, Inc. (Nasdaq: ZVSA, or “ZyVersa” or the “Company”), a clinical stage specialty biopharmaceutical company developing first-in-class drugs for treatment of renal and inflammatory diseases with high unmet needs, announces that its board of directors has approved a 1-for-35 reverse stock split of the Company’s common stock. The board of directors has also approved an increase in the Company’s authorized shares of capital stock. The Company’s stockholders approved the reverse stock split and the increase in authorized capital stock at the Company’s Annual Meeting of Stockholders held on October 31, 2023. The stockholders granted the board of directors the authority to determine the exact split ratio and when to proceed with the reverse stock split.

 

The reverse stock split will become effective on December 4, 2023 at 4:01 pm, Eastern Time, (“Effective Time”) and the Company’s common stock is expected to begin trading on a reverse stock split-adjusted basis on The Nasdaq Global Market (“Nasdaq”) on December 5, 2023 at market open under the existing ticker symbol, “ZVSA.” The reverse stock split is intended to increase the price per share of the Company’s common stock to allow the Company to demonstrate compliance with the $1.00 minimum bid price requirement for continued listing on Nasdaq, among other benefits.

 

As of the Effective Time, every 35 shares of the Company’s issued and outstanding common stock will be combined into one share of common stock. The par value per share of our common stock will remain unchanged at $0.0001. Proportional adjustments will be made to the number of shares of common stock issuable upon the exercise of the Company’s equity awards, convertible securities and warrants, as well as the applicable exercise price, and the number of shares authorized and reserved for issuance pursuant to the Company’s equity incentive plans.

 

No fractional shares will be issued as a result of the reverse stock split; rather, the Company will issue an additional fraction of a share of common stock to round the number of shares to the nearest whole share, so no stockholder will hold fractional shares following the reverse stock split.

 

The Company’s transfer agent, Continental Stock & Trust Company, will serve as the exchange agent for the reverse stock split. Registered stockholders holding pre-reverse stock split shares of common stock electronically in book-entry form are not required to take any action to receive post-reverse stock split shares. Those stockholders who hold their shares in brokerage accounts or in “street name” will have their positions automatically adjusted to reflect the reverse stock split, subject to each broker’s particular processes, and will not be required to take any action in connection with the reverse stock split.

 

Likewise, effective November 30, 2023, the Company amended its certificate of incorporation to increase the authorized number of shares of the Company’s capital stock from 111,000,000 to 251,000,000 and the number of authorized shares of common stock from 110,000,000 to 250,000,000.

 

Additional information about the reverse stock split and increase in authorized capital stock can be found in the Company’s definitive proxy statement filed with the Securities and Exchange Commission on September 13, 2023, a copy of which is available at www.sec.gov.

 

About ZyVersa Therapeutics

 

ZyVersa (Nasdaq: ZVSA) is a clinical stage specialty biopharmaceutical company leveraging advanced, proprietary technologies to develop first-in-class drugs for patients with renal and inflammatory diseases who have significant unmet medical needs. The Company is currently advancing a therapeutic development pipeline with multiple programs built around its two proprietary technologies – Cholesterol Efflux Mediator™ VAR 200 for treatment of kidney diseases, and Inflammasome ASC Inhibitor IC 100, targeting damaging inflammation associated with numerous CNS and other inflammatory diseases. For more information, please visit www.zyversa.com.

 

 
 

 

Cautionary Statement Regarding Forward-Looking Statements

 

Certain statements contained in this press release regarding matters that are not historical facts, are forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995. These include statements regarding management’s intentions, plans, beliefs, expectations, or forecasts for the future, and, therefore, you are cautioned not to place undue reliance on them. No forward-looking statement can be guaranteed, and actual results may differ materially from those projected. ZyVersa Therapeutics, Inc (“ZyVersa”) uses words such as “anticipates,” “believes,” “plans,” “expects,” “projects,” “future,” “intends,” “may,” “will,” “should,” “could,” “estimates,” “predicts,” “potential,” “continue,” “guidance,” and similar expressions to identify these forward-looking statements that are intended to be covered by the safe-harbor provisions. Such forward-looking statements are based on ZyVersa’s expectations and involve risks and uncertainties; consequently, actual results may differ materially from those expressed or implied in the statements due to a number of factors, including the effect that the reverse stock split may have on the price of ZyVersa’s common stock and ZyVersa’s ability to maintain its listing on The Nasdaq Global Market.

 

New factors emerge from time-to-time, and it is not possible for ZyVersa to predict all such factors, nor can ZyVersa assess the impact of each such factor on the business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements. Forward-looking statements included in this press release are based on information available to ZyVersa as of the date of this press release. ZyVersa disclaims any obligation to update such forward-looking statements to reflect events or circumstances after the date of this press release, except as required by applicable law.

 

Corporate and IR Contact:

Karen Cashmere

Chief Commercial Officer

kcashmere@zyversa.com

786-251-9641

 

Media Contacts

Tiberend Strategic Advisors, Inc.

Casey McDonald

cmcdonald@tiberend.com

646-577-8520

 

Dave Schemelia

dschemelia@tiberend.com

609-468-9325

 

 

 

 EX-101.SCH 4 zvsa-20231130.xsd XBRL SCHEMA FILE 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 5 zvsa-20231130_lab.xml XBRL LABEL FILE Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] EX-101.PRE 6 zvsa-20231130_pre.xml XBRL PRESENTATION FILE XML 7 R1.htm IDEA: XBRL DOCUMENT v3.23.3
Cover
Nov. 30, 2023
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Nov. 30, 2023
Current Fiscal Year End Date --12-31
Entity File Number 001-41184
Entity Registrant Name ZYVERSA THERAPEUTICS, INC.
Entity Central Index Key 0001859007
Entity Tax Identification Number 86-2685744
Entity Incorporation, State or Country Code DE
Entity Address, Address Line One 2200 N. Commerce Parkway
Entity Address, Address Line Two Suite 208
Entity Address, City or Town Weston
Entity Address, State or Province FL
Entity Address, Postal Zip Code 33326
City Area Code (754)
Local Phone Number 231-1688
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock, par value $0.0001 per share
Trading Symbol ZVSA
Security Exchange Name NASDAQ
Entity Emerging Growth Company true
Elected Not To Use the Extended Transition Period false
XML 8 form8-k_htm.xml IDEA: XBRL DOCUMENT 0001859007 2023-11-30 2023-11-30 iso4217:USD shares iso4217:USD shares false --12-31 0001859007 8-K 2023-11-30 ZYVERSA THERAPEUTICS, INC. DE 001-41184 86-2685744 2200 N. Commerce Parkway Suite 208 Weston FL 33326 (754) 231-1688 false false false false Common Stock, par value $0.0001 per share ZVSA NASDAQ true false EXCEL 9 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx M4$L#!!0 ( *A=?E<'04UB@0 +$ 0 9&]C4')O<',O87!P+GAM M;$V./0L",1!$_\IQO;=!P4)B0-!2L+(/>QLOD&1#LD)^OCG!CVX>;QA&WPIG M*N*I#BV&5(_C(I(/ !47BK9.7:=N')=HI6-Y #OGDK7A.YNJQ<&4GPZ4A!0W_J=0U[R;UEA_6\#MI7E!+ P04 M " "H77Y7XHT8-.X K @ $0 &1O8U!R;W!S+V-O&ULS9+! M3L,P#(9?!>7>NFEAAZCK91,GD)"8!.(6)=X6K6FBQ*C=VY.&K1."!^ 8^\_G MSY);Y85R 5^"\QC(8+R;;#]$H?R:'8F\ (CJB%;&,B6&U-R[8"6E9SB E^HD M#PAU5:W (DDM2<(,+/Q"9%VKE5 !);EPP6NUX/UGZ#-,*\ >+0X4@9<<6#=/ M].>I;^$&F&&$P<;O NJ%F*M_8G,'V"4Y1;.DQG$LQR;GT@X621A'^_1S80RY8-[9)-NIL\!"SI^\Y%1^?H.'GS[BYBZ(:(E/)X M8-DOV]:[MR_>X%#BVR]*+ M41B1%G\@M MNN01.+5)#3(3/PB=AIAJ4!P"I DQEJ&&^+3&K!'@$WVWO@C(WXV(]ZMOFCU7 MH5A)VH3X$$8:XIQSYG/1;/L'I4;1]E6\W*.76!4!EQC?-*HU+,76>)7 \:V< M/!T3$LV4"P9!AI@S M&L%&KQMUAVC2/'K^!?F<-0HACA*FNVB<5@$_9Y>PTG!Z(++9OVX?H;5,VPLCO='U!=*Y \FIS_I,C0' MHYI9";V$5FJ?JH,@H%\;D>/N5Z> HWEL:\4*Z">P'_T=HWPJOX@L Y M?RY]SZ7ON?0]H=*W-R-]9\'3BUO>1FY;Q/NN,=K7-"XH8U=RSTS0LS0[=R2^JVE+ZU)CA* M]+',<$X>RPP[9SR2';9WH!TU^_9==N0CI3!3ET.X&D*^ VVZG=PZ.)Z8D;D* MTU*0;\/YZ<5X&N(YV02Y?9A7;>?8T='[Y\%1L*/O/)8=QXCRHB'NH8:8S\-# MAWE[7YAGE<90-!1M;*PD+$:W8+C7\2P4X&1@+: '@Z]1 O)256 Q6\8#*Y"B M?$R,1>APYY=<7^/1DN/;IF6U;J\I=QEM(E(YPFF8$V>KRMYEL<%5'<]56_*P MOFH]M!5.S_Y9KF4Q9Z;RWRT,"2Q;B%D2XDU=[=7GFYRN>B)V^I=W MP6#R_7#)1P_E.^=?]%U#KG[VW>/Z;I,[2$R<><41 71% B.5' 86%S+D4.Z2 MD 83 >LX=SFWJXPD6L_UC6'ODRWSEPVSK> U[F M$RQ#I'[!?8J*@!&K8KZZKT_Y)9P[M'OQ@2";_-;;I/;=X Q\U*M:I60K$3]+ M!WP?D@9CC%OT-%^/%&*MIK&MQMHQ#'F 6/,,H68XWX=%FAHSU8NL.8T*;T'5 M0.4_V]0-:/8--!R1!5XQF;8VH^1."CS<_N\-L,+$CN'MB[\!4$L#!!0 ( M *A=?E?%!RV&PO=V]R:W-H965T&UL MC9AO<^(V$,;?WZ?0T$[G;B: ;?XF!68((3WF!I'J5]9:QS?UNO+6+*2J)F(6 MP3=+(4.JX52NZBJ6C/II4!C4'<@BQ45$)%OV*T/[YM;I MF(#TCF?.MNKDF)A760CQ9DXF?K]B&2(6,$\;"0H?&S9B06"4@..?@V@E>Z8) M/#T^JM^G+P\OLZ"*C43PPGV][E>Z%>*S)4T"_2BV7]GAA5I&SQ.!2O^3[?[> MEE4A7J*T" _!0!#R:/])WP\#<1+0;)\)< X!3LJ]?U!*>4\0=KL/<\Z$3<6F1AK6%7$L MI_'?\#H09!A.AN&D>@T,@_PU7"@M(5%_%Q'M%9K%"F;VWJB8>JQ?@>FIF-RP MRN"W7^RV]3O"U\CX&ICZX$YX":[F!7!X>'=ZC<$HIE!-%&5(1#X*<5] M0%=%%'C\D@:*(1RMC*-UV6#,F.3")^/()S#Y"L<%5\JF4=D\:F=H;51PE$B9 M#A!7'@W(3T8EBH>K5:NV4VW8"%+J7\#RR%3V*,'$E"\:NV[JVK Z"95NY9UJ7@,WI M.YGX0,>7W*-ID3F?VQ+);KOJM+NM3A/+KGWBZO8EA)/($S(6,H6[(JZ&94"$ M)".1P)C"T J_,.DEZG=C##+W?!NU["/DT/?!L-75\8 \P'WD1U1,ADLZT(U\ M(O WK<'+A2&3'B,S*M^V=(-6S<[#^29;-Q)L6&1UYQOG'-^P<,+:\: M-F[T']%F0FEPG%<>GU\BN&*CT7#:&%M>.6S<]M,$#J'C/H^""WSNM)I?,)2\ M:-BXVS\(4U1G:Q%A5:Q$Q&G85;O=16=[7B%LW-A?)->:1>E:3Z*#"ZM"*ERH MK#=R\N+@X$[NBH![7/-H1;[#!)>B5DIWT_+A9_X]LHE0"9*6 N&PI8&[V#N[,\T2H>G0 MO1O^B3'EAN]<9/AC:!!69I3^ 6]-C82TZ@XP;B@E@F:M]SNG9)?"F:_@OED M*F"E"O*D&-%K!F.GS:KP">0U4CQM-O<_OPIA\6><72'UDXT$LRGSG9KA421@ M2Q"R:AU(D-SO<^Q/M(C3O86%T%J$Z>&:45B]Y@;X?BF$/IZ8[8ILMVGP+U!+ M P04 " "H77Y7GZ ;\+$" #B# #0 'AL+W-T>6QEO%DN7/ZZZ>S;"=I=67=A['- MHN6/O.-%Q[I#)6,>=5 M6R=M8SDK6W!2,EG>W&2)8D+38JT[=:=<2PZFTVY#;VA2K"NCSY:4!H-?RA0G MCTQNZ)9)L;=B6,N4D*=@7H+A8*2QQ'DJ?$,78&F? KP(&K XU7=>&18/QA<0&>7=J?$,:\M.B^4M/3L, M/S[)WMB2VSG-@DZF8BUY!72LJ(_PZTR3 .B<45XH!:N-9@.'R6,4?-@#E_(! M6OBMNHK=5R3TXE,);2"PU4GTA$8QA D*Q+^,%F)?A+W]K;"D$8_&?>S\;O2@ M?^^,X_>65Z(?]+Z:\V/1%WATUC3R]$&*6BL>]O[+"8LUF_S(T5CQY+/!I!R\ M@5M*'KEUXG!I^6%9L^.]FZ:IKW#.RW^0\Y^M<\TUMTQ>DO:C_S=7^2V,D_'T M7!S1JP,Z6PEY7>>9 ]IV03NA1.XJRY/K%.?7A'=O["_PJOE]?\HIU MTNUF<$//\A=>BD[E\ZI[J,NXZBQ_AOMHD\%G' M!QR>(W?#$T%^@2O&+(= M/EB>N$_NG_A.\SQ-LPRKZ'8;9;#%ZI9E\!>/AG$##RP/9'I;K?%NXQ/R^AQ@ M/7UM0K"=XI.([12O-2#QNH%'GL>[C>4!#ZP+V.Q _G@>F*FX3YI"5S%NV G& MD3S'$)C%^(QF&5*=##[Q_F"G)$WS/(X %F>0IA@"IQ%', ; 4/2='@//GL? M)=-[*CG_5U/\!%!+ P04 " "H77Y7EXJ[', 3 @ "P %]R96QS M+RYR96QSG9*Y;L,P#$!_Q=">, ?0(8@S9?$6!/D!5J(/V!(%BD6=OZ_:I7&0 M"QEY/3P2W!YI0.TXI+:+J1C]$%)I6M6X 4BV)8]ISI%"KM0L'C6'TD!$VV-# ML%HL/D N&6:WO606IW.D5XA-/E_G;@2=&A(E@6FD7)TZ(=I7\=Q_:0T^FO8R*T>EOH^7%H M5 J.W&,EC'%BM/XU@LD/['X 4$L#!!0 ( *A=?E>JQ"(6,P$ "(" / M >&PO=V]R:V)O;VLN>&ULC5'1;L(P#/R5*A^P%K0A#5%>0-N0I@V-B??0 MNM0BB2O'A8VOG]NJ&M)>]I31=B;FJ19IZFL:C!VWA' M#02=5,3>BD(^IK%AL&6L <2[=)IEL]1;#&:Y&+6VG-X"$B@$*2C9$7N$2_R= M=S Y8\0#.I3OW/1W!R;Q&-#C%B/%*0:S;%4S.Y68R#/; @L4? M>M>9_+2'V#-B#Q]6C>1FEJE@A1REW^CUK7H\@RX/J!5Z0B? :ROPS-0V&(Z= MC*9(;V+T/8SG4.*<_U,C5146L*:B]1!DZ)'!=09#K+&))@G60VY6= ;N\N@# MFW+()FKJIBF>HPYX4P[V1D\E5!B@?%.9J+SV4VPYZ8Y>9WK_,'G4'EKG5LJ] MAU>RY1AQ_)[E#U!+ P04 " "H77Y7)!Z;HJT #X 0 &@ 'AL+U]R M96QS+W=O[IFBG#S^0W1UW6E\./VR./ /,+Q= MZ*E%9"E*%1KD3,)HMC;!4N++3):BJ#(9BBJ6<%H@XLD@;6E6?;!/3K3G>1,)KM\,<'AT_@%02P,$% @ J%U^5V60>9(9 0 SP, !, !; M0V]N=&5N=%]4>7!E&ULK9--3L,P$(6O$F5;)2XL6*"F&V +77 !8T\: MJ_Z39UK2VS-.VDJ@$A6%3:QXWKS/GI>LWH\1L.B=]=B4'5%\% )5!TYB'2)X MKK0A.4G\FK8B2K636Q#WR^6#4,$3>*HH>Y3KU3.T.EY&TWP39G 8ED\ MC<+,:DH9HS5*$M?%P>L?E.I$J+EST&!G(BY84(JKA%SY'7#J>SM 2D9#L9&) M7J5CE>BM0#I:P'K:XLH90]L:!3JHO>.6&F,"J;$#(&?KT70Q32:>,(S/N]G\ MP68*R,I-"A$YL01_QYTCR=U59"-(9*:O>"&R]>S[04Y;@[Z1S>/]#&DWY(%B M6.;/^'O&%_\;SO$1PNZ_/[&\UDX:?^:+X3]>?P%02P$"% ,4 " "H77Y7 M!T%-8H$ "Q $ @ $ 9&]C4')O<',O87!P+GAM M;%!+ 0(4 Q0 ( *A=?E?BC1@T[@ "L" 1 " :\ M !D;V-097)PC$ 8 )PG M 3 " &UL4$L! A0# M% @ J%U^5\4'+9R]! >1( !@ ("!#0@ 'AL+W=O M?H!OPL0( .(, M - " 0 - !X;"]S='EL97,N>&UL4$L! A0#% @ MJ%U^5Y>*NQS $P( L ( !W \ %]R96QS+RYR96QS M4$L! A0#% @ J%U^5ZK$(A8S 0 (@( \ ( !Q1 M 'AL+W=O7!E&UL4$L%!@ ) D /@( %04 $! end XML 10 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 11 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 12 FilingSummary.xml IDEA: XBRL DOCUMENT 3.23.3 html 1 25 1 false 0 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://zyversa.com/role/Cover Cover Cover 1 false false All Reports Book All Reports form8-k.htm zvsa-20231130.xsd zvsa-20231130_lab.xml zvsa-20231130_pre.xml http://xbrl.sec.gov/dei/2023 true false JSON 14 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "form8-k.htm": { "nsprefix": "ZVSA", "nsuri": "http://zyversa.com/20231130", "dts": { "inline": { "local": [ "form8-k.htm" ] }, "schema": { "local": [ "zvsa-20231130.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd" ] }, "labelLink": { "local": [ "zvsa-20231130_lab.xml" ] }, "presentationLink": { "local": [ "zvsa-20231130_pre.xml" ] } }, "keyStandard": 25, "keyCustom": 0, "axisStandard": 0, "axisCustom": 0, "memberStandard": 0, "memberCustom": 0, "hidden": { "total": 3, "http://xbrl.sec.gov/dei/2023": 3 }, "contextCount": 1, "entityCount": 1, "segmentCount": 0, "elementCount": 59, "unitCount": 3, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2023": 25 }, "report": { "R1": { "role": "http://zyversa.com/role/Cover", "longName": "00000001 - Document - Cover", "shortName": "Cover", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "AsOf2023-11-30", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "b", "span", "p", "body", "html" ], "reportCount": 1, "baseRef": "form8-k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2023-11-30", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "b", "span", "p", "body", "html" ], "reportCount": 1, "baseRef": "form8-k.htm", "first": true, "unique": true } } }, "tag": { "dei_DocumentQuarterlyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentQuarterlyReport", "presentation": [ "http://zyversa.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Quarterly Report", "documentation": "Boolean flag that is true only for a form used as an quarterly report." } } }, "auth_ref": [ "r12" ] }, "dei_NoTradingSymbolFlag": { "xbrltype": "trueItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "NoTradingSymbolFlag", "presentation": [ "http://zyversa.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "No Trading Symbol Flag", "documentation": "Boolean flag that is true only for a security having no trading symbol." } } }, "auth_ref": [] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "WrittenCommunications", "presentation": [ "http://zyversa.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r18" ] }, "dei_EntityAddressAddressLine3": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine3", "presentation": [ "http://zyversa.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Three", "documentation": "Address Line 3 such as an Office Park" } } }, "auth_ref": [] }, "dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntitySmallBusiness", "presentation": [ "http://zyversa.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } }, "auth_ref": [ "r2" ] }, "dei_DocumentAccountingStandard": { "xbrltype": "accountingStandardItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentAccountingStandard", "presentation": [ "http://zyversa.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Accounting Standard", "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'." } } }, "auth_ref": [ "r13" ] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": [ "http://zyversa.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFileNumber", "presentation": [ "http://zyversa.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityBankruptcyProceedingsReportingCurrent", "presentation": [ "http://zyversa.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Bankruptcy Proceedings, Reporting Current", "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element." } } }, "auth_ref": [ "r6" ] }, "dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCurrentReportingStatus", "presentation": [ "http://zyversa.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [] }, "dei_Security12gTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12gTitle", "presentation": [ "http://zyversa.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(g) Security", "documentation": "Title of a 12(g) registered security." } } }, "auth_ref": [ "r5" ] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": [ "http://zyversa.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CityAreaCode", "presentation": [ "http://zyversa.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "dei_AnnualInformationForm": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AnnualInformationForm", "presentation": [ "http://zyversa.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Annual Information Form", "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form." } } }, "auth_ref": [ "r14" ] }, "dei_DocumentAnnualReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentAnnualReport", "presentation": [ "http://zyversa.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Annual Report", "documentation": "Boolean flag that is true only for a form used as an annual report." } } }, "auth_ref": [ "r11", "r13", "r14" ] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalYearFocus", "presentation": [ "http://zyversa.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12bTitle", "presentation": [ "http://zyversa.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r1" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "TradingSymbol", "presentation": [ "http://zyversa.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": [ "http://zyversa.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_SecurityReportingObligation": { "xbrltype": "securityReportingObligationItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityReportingObligation", "presentation": [ "http://zyversa.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Reporting Obligation", "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act." } } }, "auth_ref": [ "r9" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityExchangeName", "presentation": [ "http://zyversa.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r4" ] }, "dei_EntityVoluntaryFilers": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityVoluntaryFilers", "presentation": [ "http://zyversa.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Voluntary Filers", "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act." } } }, "auth_ref": [] }, "dei_EntityExTransitionPeriod": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityExTransitionPeriod", "presentation": [ "http://zyversa.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Elected Not To Use the Extended Transition Period", "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards." } } }, "auth_ref": [ "r19" ] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SolicitingMaterial", "presentation": [ "http://zyversa.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r10" ] }, "dei_EntityPrimarySicNumber": { "xbrltype": "sicNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityPrimarySicNumber", "presentation": [ "http://zyversa.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Primary SIC Number", "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity." } } }, "auth_ref": [ "r14" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://zyversa.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r2" ] }, "dei_DocumentPeriodStartDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodStartDate", "presentation": [ "http://zyversa.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period Start Date", "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format." } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine2", "presentation": [ "http://zyversa.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] }, "dei_Extension": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Extension", "presentation": [ "http://zyversa.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Extension", "documentation": "Extension number for local phone number." } } }, "auth_ref": [] }, "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFilerCategory", "presentation": [ "http://zyversa.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [ "r2" ] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": [ "http://zyversa.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r2" ] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": [ "http://zyversa.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_DocumentRegistrationStatement": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentRegistrationStatement", "presentation": [ "http://zyversa.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Registration Statement", "documentation": "Boolean flag that is true only for a form used as a registration statement." } } }, "auth_ref": [ "r0" ] }, "dei_CountryRegion": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CountryRegion", "presentation": [ "http://zyversa.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Country Region", "documentation": "Region code of country" } } }, "auth_ref": [] }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentsIncorporatedByReferenceTextBlock", "presentation": [ "http://zyversa.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Documents Incorporated by Reference [Text Block]", "documentation": "Documents incorporated by reference." } } }, "auth_ref": [ "r3" ] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": [ "http://zyversa.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r2" ] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LocalPhoneNumber", "presentation": [ "http://zyversa.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "dei_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentTransitionReport", "presentation": [ "http://zyversa.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth_ref": [ "r15" ] }, "dei_AuditedAnnualFinancialStatements": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AuditedAnnualFinancialStatements", "presentation": [ "http://zyversa.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Audited Annual Financial Statements", "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements." } } }, "auth_ref": [ "r14" ] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://zyversa.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_DocumentShellCompanyEventDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentShellCompanyEventDate", "presentation": [ "http://zyversa.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Event Date", "documentation": "Date of event requiring a shell company report." } } }, "auth_ref": [ "r13" ] }, "dei_EntityPublicFloat": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityPublicFloat", "crdr": "credit", "presentation": [ "http://zyversa.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Public Float", "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter." } } }, "auth_ref": [] }, "dei_EntityAddressCountry": { "xbrltype": "countryCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCountry", "presentation": [ "http://zyversa.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Country", "documentation": "ISO 3166-1 alpha-2 country code." } } }, "auth_ref": [] }, "dei_OtherReportingStandardItemNumber": { "xbrltype": "otherReportingStandardItemNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "OtherReportingStandardItemNumber", "presentation": [ "http://zyversa.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Other Reporting Standard Item Number", "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS." } } }, "auth_ref": [ "r13" ] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodEndDate", "presentation": [ "http://zyversa.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://zyversa.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r2" ] }, "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCommonStockSharesOutstanding", "presentation": [ "http://zyversa.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": [] }, "dei_DocumentShellCompanyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentShellCompanyReport", "presentation": [ "http://zyversa.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Report", "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act." } } }, "auth_ref": [ "r13" ] }, "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityInteractiveDataCurrent", "presentation": [ "http://zyversa.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } }, "auth_ref": [ "r16" ] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalPeriodFocus", "presentation": [ "http://zyversa.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://zyversa.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://zyversa.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r7" ] }, "dei_AmendmentDescription": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentDescription", "presentation": [ "http://zyversa.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Description", "documentation": "Description of changes contained within amended document." } } }, "auth_ref": [] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://zyversa.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CurrentFiscalYearEndDate", "presentation": [ "http://zyversa.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "dei_EntityWellKnownSeasonedIssuer": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityWellKnownSeasonedIssuer", "presentation": [ "http://zyversa.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Well-known Seasoned Issuer", "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A." } } }, "auth_ref": [ "r17" ] }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityShellCompany", "presentation": [ "http://zyversa.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": [ "r2" ] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementTenderOffer", "presentation": [ "http://zyversa.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r8" ] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12" }, "r1": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r2": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r3": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-23" }, "r4": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r5": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "g" }, "r6": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12, 13, 15d" }, "r7": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r8": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r9": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "15", "Subsection": "d" }, "r10": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Section": "14a", "Number": "240", "Subsection": "12" }, "r11": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-K", "Number": "249", "Section": "310" }, "r12": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-Q", "Number": "240", "Section": "308", "Subsection": "a" }, "r13": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Number": "249", "Section": "220", "Subsection": "f" }, "r14": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Number": "249", "Section": "240", "Subsection": "f" }, "r15": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Section": "13", "Subsection": "a-1" }, "r16": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-T", "Number": "232", "Section": "405" }, "r17": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "405" }, "r18": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" }, "r19": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "7A", "Section": "B", "Subsection": "2" } } } ZIP 15 0001493152-23-043170-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001493152-23-043170-xbrl.zip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